Skip to main content
SpringerLink
Log in

Nonneoplastic and Neoplastic Ureteral and Renal Pelvis Disease

  • Chapter
  • First Online:
The Urinary Tract

  • 974 Accesses

Abstract

Although any form of carcinoma identified in the urinary tract may arise in the upper tract, the most common cancer at this site is urothelial carcinoma (UC). The occurrence of upper urinary tract UC is rare, but may occur anywhere from the urothelium of the renal pelvis to the distal ureter (Fig. 14.1). It accounts for approximately 8 % of all renal tumors and 5 % of all tumors of the urinary tract [1–4]. Its incidence, however, increases among those who are exposed to particular chemicals or who are genetically susceptible. Urothelial carcinoma of the upper urinary tract occurs about three to four times more frequently in the renal pelvis than in the ureter. Bilateral synchronous upper urinary tract UC represents about 3 % of the urothelial carcinomas [5]. Although sharing histological and molecular similarities with bladder UC [6, 7], upper tract UC has anatomic differences that may affect disease prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52(4):594–601.

    Article  PubMed  CAS  Google Scholar 

  2. Kirkali Z, Tuzel E. Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol. 2003;47(2):155–69.

    Article  PubMed  Google Scholar 

  3. Gupta NP, Sharma N, Kumar R. Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder. Urology. 2009;73(3):592–6; discussion 596–7. 10.1016/j.urology.2008.04.051.

    Google Scholar 

  4. Gupta R, Paner GP, Amin MB. Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv Anat Pathol. 2008;15(3):127–39. doi: 10.1097/PAP.0b013e31817145a9.

    Article  PubMed  Google Scholar 

  5. Rouprêt M, Yates DR, Comperat E, Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol. 2008;54(6):1226–36. Epub 2008 Aug 12. Review.

    Google Scholar 

  6. Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 ­mutation status: a prospective study. Eur Urol. 2008;54(4):835–43. Epub 2007 Dec 26.

    Google Scholar 

  7. Zhang Z, Furge KA, Yang XJ, Teh BT, Hansel DE. Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med Genomics. 2010;3:58.

    Article  PubMed  CAS  Google Scholar 

  8. Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000;164(5):1523–5.

    Article  PubMed  CAS  Google Scholar 

  9. Olgac S, Mazumdar M, Dalbagni G, Reuter VE. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol. 2004;28(12):1545–52.

    Article  PubMed  Google Scholar 

  10. Sagalowsky A, Jarrett TW. Management of urothelial tumors of the renal pelvis and ureter. In: Wein AJ, editor. Campbell-Walsh urology, 2. 9th ed. Philadelphia: Saunders; 2007.

    Google Scholar 

  11. Sanderson KM, Rouprêt M. Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments. BJU Int. 2007;100(1):11–6. Epub 2007 Apr 8. Review.

    Google Scholar 

  12. Denzinger S, Mohren K, Knuechel R, Wild PJ, Burger M, Wieland WF, et al. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. Hum Pathol. 2006;37(2):143–51. Epub 2005 Dec 15.

    Google Scholar 

  13. McLaughlin JK, Silverman DT, Hsing AW, et al. Cigarette smoking and cancers of the renal pelvis and ureter. Cancer Res. 1992;52(2):254–7.

    PubMed  CAS  Google Scholar 

  14. McCredie M, Stewart JH, Ford JM. Analgesics and tobacco as risk factors for cancer of the ureter and renal pelvis. J Urol. 1983;130(1):28–30.

    PubMed  CAS  Google Scholar 

  15. Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant. 1999;14(12):2892–7.

    Article  PubMed  CAS  Google Scholar 

  16. Ross RK, Paganini-Hill A, Landolph J, Gerkins V, Henderson BE. Analgesics, cigarette smoking, and other risk factors for cancer of the renal pelvis and ureter. Cancer Res. 1989;49(4):1045–8.

    PubMed  CAS  Google Scholar 

  17. Colin P, Koenig P, Ouzzane A, et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int. 2009;104(10):1436–40. doi:10.1111/j.1464-410X.2009.08838.x.

    Article  PubMed  CAS  Google Scholar 

  18. Hung RJ, Boffetta P, Brennan P, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004;110(4):598–604. doi:10.1002/ijc.20157.

    Article  PubMed  CAS  Google Scholar 

  19. McLaughlin JK, Blot WJ, Mandel JS, Schuman LM, Mehl ES, Fraumeni Jr JF. Etiology of cancer of the renal pelvis. J Natl Cancer Inst. 1983;71(2):287–91.

    PubMed  CAS  Google Scholar 

  20. McCredie M, Stewart JH, Mahony JF. Is phenacetin responsible for analgesic nephropathy in New South Wales? Clin Nephrol. 1982;17(3):134–40.

    PubMed  CAS  Google Scholar 

  21. McCredie M, Ford JM, Taylor JS, Stewart JH. Analgesics and cancer of the renal pelvis in New South Wales. Cancer. 1982;49(12):2617–25.

    Article  PubMed  CAS  Google Scholar 

  22. Jensen OM, Knudsen JB, Tomasson H, Sorensen BL. The Copenhagen case–control study of renal pelvis and ureter cancer: role of analgesics. Int J Cancer. 1989;44(6):965–8.

    Article  PubMed  CAS  Google Scholar 

  23. Holmang S, Johansson SL. Synchronous bilateral ureteral and renal pelvic carcinomas: incidence, etiology, treatment and outcome. Cancer. 2004;101(4):741–7. doi:10.1002/cncr.20395.

    Article  PubMed  Google Scholar 

  24. Stewart JH, Hobbs JB, McCredie MR. Morphologic evidence that analgesic-induced kidney pathology contributes to the progression of tumors of the renal pelvis. Cancer. 1999;86(8):1576–82.

    Article  PubMed  CAS  Google Scholar 

  25. Lynch HT, Boland CR, Rodriguez-Bigas MA, Amos C, Lynch JF, Lynch PM. Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol. 2007;25(23):3534–42.

    Article  PubMed  Google Scholar 

  26. Stefanovic V, Polenakovic M. Fifty years of research in Balkan endemic nephropathy: where are we now? Nephron Clin Pract. 2009;112(2):c51–6. doi:10.1159/000213081.

    Article  PubMed  CAS  Google Scholar 

  27. Petkovic SD. Epidemiology and treatment of renal pelvic and ureteral tumors. J Urol. 1975;114(6):858–65.

    PubMed  CAS  Google Scholar 

  28. Dragicevic D, Djokic M, Pekmezovic T, et al. Survival of patients with transitional cell carcinoma of the ureter and renal pelvis in Balkan endemic nephropathy and non-endemic areas of Serbia. BJU Int. 2007;99(6):1357–62. doi:10.1111/j.1464-410X.2007.06793.x.

    Article  PubMed  Google Scholar 

  29. Cukuranovic R, Petrovic B, Cukuranovic Z, Stefanovic V. Balkan endemic nephropathy: a decreasing incidence of the disease. Pathol Biol (Paris). 2000;48(6):558–61.

    CAS  Google Scholar 

  30. Markovic N, Ignjatovic I, Cukuranovic R, Petrovic B, Kocic B, Stefanovic V. Decreasing incidence of urothelial cancer in a Balkan endemic nephropathy region in Serbia. A surgery based study from 1969 to 1998. Pathol Biol (Paris). 2005;53(1):26–9. doi:10.1016/j.patbio.2004.01.008.

    Article  Google Scholar 

  31. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341(8842):387–91.

    Article  PubMed  CAS  Google Scholar 

  32. Depierreux M, Van Damme B, Van den Houte K, Van her weghem JL. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis. 1994;24(2):172–80.

    PubMed  CAS  Google Scholar 

  33. Cosyns JP, Jadoul M, Squifflet JP, De Plaen JF, Ferluga D, van Ypersele de Strihou C. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int. 1994;45(6):1680–8.

    Article  PubMed  CAS  Google Scholar 

  34. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. Identification of aristolochic acid in Chinese herbs. Lancet. 1994;343(8890):174.

    Article  PubMed  CAS  Google Scholar 

  35. Chen L, Mei N, Yao L, Chen T. Mutations induced by carcinogenic doses of aristolochic acid in kidney of Big Blue transgenic rats. Toxicol Lett. 2006;165(3):250–6. doi:10.1016/j.toxlet.2006.04.008.

    Article  PubMed  CAS  Google Scholar 

  36. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 1996;56(9):2025–8.

    PubMed  CAS  Google Scholar 

  37. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342(23):1686–92.

    Article  PubMed  CAS  Google Scholar 

  38. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9–21. Review.

    Google Scholar 

  39. Shiga Y, Suzuki K, Tsutsumi M, Ishikawa S. Transitional cell carcinoma of the renal pelvis in a patient with cyclophosphamide therapy for malignant lymphoma: a case report and literature review. Hinyokika Kiyo. 2002;48(5):301–5.

    PubMed  Google Scholar 

  40. Volkmer BG, Seidl-Schlick EM, Bach D, Romics I, Kleinschmidt K. As such, cyclophosphamide is contraindicated in patients with a history of UC. Clin Rheumatol. 2005;24:319–23.

    Article  PubMed  Google Scholar 

  41. Jensen OM, Knudsen JB, McLaughlin JK, Sorensen BL. The Copenhagen case–control study of renal pelvis and ureter cancer: role of smoking and occupational exposures. Int J Cancer. 1988;41(4):557–61.

    Article  PubMed  CAS  Google Scholar 

  42. Racioppi M, D’Addessi A, Alcini A, Destito A, Alcini E. Clinical review of 100 consecutive surgically treated patients with upper urinary tract transitional tumours. Br J Urol. 1997;80(5):707–11.

    Article  PubMed  CAS  Google Scholar 

  43. Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol. 2010;57(6):1072–9. Epub 2009 Jul 15.

    Google Scholar 

  44. van der Poel HG, Antonini N, van Tinteren H, Horenblas S. Upper urinary tract cancer: location is correlated with prognosis. Eur Urol. 2005;48(3):438–44. doi:10.1016/j.eururo.2005.03.009.

    Article  PubMed  Google Scholar 

  45. Brausi MA, Gavioli M, De LUC G, et al. Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival. Eur Urol. 2007;52(5):1414–8. doi:10.1016/j.eururo.2007.04.070.

    Article  PubMed  Google Scholar 

  46. Brown GA, Busby JE, Wood CG, et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm? BJU Int. 2006;98(6):1176–80. doi:10.1111/j.1464-410X.2006.06524.x.

    Article  PubMed  Google Scholar 

  47. Hong B, Park S, Hong JH, Kim CS, Ro JY, Ahn H. Prognostic value of lymphovascular invasion in transitional cell carcinoma of upper urinary tract. Urology. 2005;65(4):692–6. doi:10.1016/j.urology.2004.11.001.

    Article  PubMed  Google Scholar 

  48. Saito K, Kawakami S, Fujii Y, Sakura M, Masuda H, Kihara K. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically. J Urol. 2007;178(6):2291–6; discussion 2296. 10.1016/j.juro.2007.08.019.

    Google Scholar 

  49. Guinan P, Vogelzang NJ, Randazzo R, Sener S, Chmiel J, Fremgen A, Sylvester J. Renal pelvic cancer: a review of 611 patients treated in Illinois 1975–1985. Cancer Incidence and End Results Committee. Urology. 1992;40(5):393–9.

    Article  PubMed  CAS  Google Scholar 

  50. Park S, Hong B, Kim CS, Ahn H. The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol. 2004;171(2 Pt 1):621–5.

    Article  PubMed  Google Scholar 

  51. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Toma H, Tanabe K. Primary site and incidence of lymph node metastases in urothelial carcinoma of upper urinary tract. Urology. 2007;69(2):265–9. doi:10.1016/j.urology.2006.10.014.

    Article  PubMed  Google Scholar 

  52. Remzi M, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 2009;103(3):307–11. Epub 2008 Oct 16.

    Google Scholar 

  53. Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, et al. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol. 2010;57(4):575–81. Epub 2009 Nov 25.

    Google Scholar 

  54. Melamed MR, Reuter VE. Pathology and staging of urothelial tumors of the kidney and ureter. Urol Clin North Am. 1993;20(2):333–47.

    PubMed  CAS  Google Scholar 

  55. Cummings KB. Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am. 1980;7(3):569–78.

    PubMed  CAS  Google Scholar 

  56. McCarron JP, Mills C, Vaughn Jr ED. Tumors of the renal pelvis and ureter: current concepts and management. Semin Urol. 1983;1(1):75–81.

    PubMed  CAS  Google Scholar 

  57. Mahadevia PS, Karwa GL, Koss LG. Mapping of urothelium in carcinomas of the renal pelvis and ureter. A report of nine cases. Cancer. 1983;51(5):890–7.

    Article  PubMed  CAS  Google Scholar 

  58. Jitsukawa S, Nakamura K, Nakayama M, Osawa A, Matsui K. Transitional cell carcinoma of kidney extending into renal vein and inferior vena cava. Urology. 1985;25(3):310–2.

    Article  PubMed  CAS  Google Scholar 

  59. Maier U, Simak R, Neuhold N. The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol. 1995;48(4):314–7.

    Article  PubMed  CAS  Google Scholar 

  60. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol. 2001;165(2):600–11. doi:10.1097/00005392-200102000-00081.

    Article  PubMed  CAS  Google Scholar 

  61. Brown FM. Urine cytology. It is still the gold standard for screening? Urol Clin North Am. 2000;27(1):25–37.

    Article  PubMed  CAS  Google Scholar 

  62. Halling KC, Kipp BR. Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol. 2008;15(5):279–86. Review.

    Google Scholar 

  63. Mian C, Mazzoleni G, Vikoler S, Martini T, Knüchel-Clark R, Zaak D, et al. Fluorescence in situ hybridisation in the diagnosis of upper urinary tract tumours. Eur Urol. 2010;58(2):288–92. Epub 2010 May 5.

    Google Scholar 

  64. Fernández MI, Parikh S, Grossman HB, Katz R, Matin SF, Dinney CP, Kamat AM. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urol Oncol. 2011. [Epub ahead of print].

    Google Scholar 

  65. Van der Aa MN, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA, et al. Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study. Eur Urol. 2009;55:659–67.

    Article  PubMed  Google Scholar 

  66. Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, et al.; Upper Tract Urothelial Carcinoma Collaborative Group. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol. 2010;184(2):453–8. Epub 2010 Jun 17.

    Google Scholar 

  67. Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer. 2000;88:1663–70.

    Article  PubMed  CAS  Google Scholar 

  68. Smith AK, Stephenson AJ, Lane BR, Larson BT, Thomas AA, Gong MC et al. Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology. 2011;78(1):82–6. Epub 2011 May 7.

    Google Scholar 

  69. Wang LJ, Wong YC, Huang CC, Wu CH, Hung SC, Chen HW. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol. 2010;183(1):48–55. doi:10.1016/j.juro.2009.08.14410.1016/j.juro.2009.08.144.

    Article  PubMed  Google Scholar 

  70. Jinzaki M, Matsumoto K, Kikuchi E, et al. Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am J Roentgenol. 2011;196(5):1102–9. doi:10.2214/AJR.10.5249.

    Article  PubMed  Google Scholar 

  71. Nawfel RD, Judy PF, Schleipman AR, Silverman SG. Patient radiation dose at CT urography and conventional urography. Radiology. 2004;232(1):126–32. doi:10.1148/radiol.2321030222.

    Article  PubMed  Google Scholar 

  72. Browne RF, Meehan CP, Colville J, Power R, Torreggiani WC. Transitional cell carcinoma of the upper urinary tract: spectrum of imaging findings. Radiographics. 2005;25(6):1609–27. doi:10.1148/rg.256045517.

    Article  PubMed  Google Scholar 

  73. Wong-You-Cheong JJ, Wagner BJ, Davis CJ Jr. Transitional cell carcinoma of the urinary tract: radiologic-pathologic correlation. Radiographics. 1998;18(1):123–42; quiz 148.

    Google Scholar 

  74. Lee TY, Ko SF, Wan YL, et al. Unusual imaging presentations in renal transitional cell carcinoma. Acta Radiol. 1997;38(6):1015–9.

    PubMed  CAS  Google Scholar 

  75. Gray Sears CL, Ward JF, Sears ST, Puckett MF, Kane CJ, Amling CL. Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. J Urol. 2002;168(6):2457–60. 10.1097/01.ju.0000036541.52816.98.

    Google Scholar 

  76. Lang EK, Macchia RJ, Thomas R, et al. Improved detection of renal pathologic features on multiphasic helical CT compared with IVU in patients presenting with microscopic hematuria. Urology. 2003;61(3):528–32.

    Article  PubMed  Google Scholar 

  77. Caoili EM, Cohan RH, Korobkin M, et al. Urinary tract abnormalities: initial experience with multi-detector row CT urography. Radiology. 2002;222(2):353–60.

    Article  PubMed  Google Scholar 

  78. Eiber M, van Oers JM, Zwarthoff EC, van der Kwast TH, Ulrich O, Helpap B, et al. Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. Am J Surg Pathol. 2007;31(6):938–46.

    Article  PubMed  Google Scholar 

  79. Darras J, Inderadjaja N, Vossaert P. Synchronous inverted papilloma of bladder and renal pelvis. Urology. 2005;65(4):798.

    Article  PubMed  Google Scholar 

  80. Lane Z, Epstein JI. Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia. Am J Surg Pathol. 2008;32:758–64.

    Article  PubMed  Google Scholar 

  81. Hartmann A, Dietmaier W, Hofstädter F, Burgart LJ, Cheville JC, Blaszyk H. Urothelial carcinoma of the upper urinary tract: inverted growth pattern is predictive of microsatellite instability. Hum Pathol. 2003;34(3):222–7.

    Article  PubMed  Google Scholar 

  82. Lopez-Beltran A, Escudero AL, Cavazzana AO, Spagnoli LG, Vicioso-Recio L. Sarcomatoid transitional cell carcinoma of the renal pelvis. A report of five cases with clinical, pathological, immunohistochemical and DNA ploidy analysis. Pathol Res Pract. 1996;192(12):1218–24.

    Google Scholar 

  83. Holmäng S, Lele SM, Johansson SL. Squamous cell carcinoma of the renal pelvis and ureter: incidence, symptoms, treatment and outcome. J Urol. 2007;178(1):51–6. Epub 2007 May 11.

    Google Scholar 

  84. Blacher EJ, Johnson DE, Abdul-Karim FW, Ayala AG. Squamous cell carcinoma of renal pelvis. Urology. 1985;25(2):124–6.

    Article  PubMed  CAS  Google Scholar 

  85. Gilligan T, Dreicer R. The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis. Semin Oncol. 2007;34:145–53.

    Article  PubMed  Google Scholar 

  86. Babaian RJ, Johnson DE. Primary carcinoma of the ureter. J Urol. 1980;123(3):357–9.

    PubMed  CAS  Google Scholar 

  87. Batata M, Grabstald H. Upper urinary tract urothelial tumors. Urol Clin North Am. 1976;3(1):79–86.

    PubMed  CAS  Google Scholar 

  88. Skinner DG. Technique of nephroureterectomy with regional lymph node dissection. Urol Clin North Am. 1978;5(1):252–60.

    PubMed  CAS  Google Scholar 

  89. Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer. 1988;62(9):2016–20.

    Article  PubMed  CAS  Google Scholar 

  90. Abaza R, Keck RW, Selman SH. Intraperitoneal chemotherapy for the prevention of transitional cell carcinoma implantation. J Urol. 2006;175(6):2317–22. doi:10.1016/S0022-5347(06), 00257-6.

    Article  PubMed  Google Scholar 

  91. Hasson HM. Open laparoscopy: a report of 150 cases. J Reprod Med. 1974;12(6):234–8.

    PubMed  CAS  Google Scholar 

  92. Li WM, Shen JT, Li CC, et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol. 2010. 10.1016/j.eururo.2009.12.032.

    Google Scholar 

  93. Palou J, Caparros J, Orsola A, Xavier B, Vicente J. Transurethral resection of the intramural ureter as the first step of nephroureterectomy. J Urol. 1995;154(1):43–4.

    Article  PubMed  CAS  Google Scholar 

  94. Geavlete P, Georgescu D, Bancu S, Mirciulescu V. Endoscopic ureteral procedures for one-step nephroureterectomy: experience in 100 cases. J Endourol. 2007;21(9):1019–24. doi:10.1089/end.2006.0426.

    Article  PubMed  Google Scholar 

  95. Giovansili B, Peyromaure M, Saighi D, Dayma T, Zerbib M, Debre B. Stripping technique for endoscopic management of distal ureter during nephroureterectomy: experience of 32 procedures. Urology. 2004;64(3):448–52; discussion 452. 10.1016/j.urology.2004.04.080.

    Google Scholar 

  96. Gill IS, Soble JJ, Miller SD, Sung GT. A novel technique for management of the en bloc bladder cuff and distal ureter during laparoscopic nephroureterectomy. J Urol. 1999;161(2):430–4.

    Article  PubMed  CAS  Google Scholar 

  97. Hattori R, Yoshino Y, Komatsu T, Matsukawa Y, Ono Y, Gotoh M. Pure laparoscopic complete excision of distal ureter with a bladder cuff for upper tract urothelial carcinoma. World J Urol. 2009;27(2):253–8. doi:10.1007/s00345-008-0337-1.

    Article  PubMed  Google Scholar 

  98. Shoma AM. Purse-string technique for laparoscopic excision of a bladder mucosal cuff in patients with transitional cell carcinoma of the upper urinary tract: initial report with intermediate follow-up. BJU Int. 2009;104(10):1505–9. doi:10.1111/j.1464-410X.2009.08598.x.

    Article  PubMed  Google Scholar 

  99. Kurzer E, Leveillee RJ, Bird VG. Combining hand assisted laparoscopic nephroureterectomy with cystoscopic circumferential excision of the distal ureter without primary closure of the bladder cuff--is it safe? J Urol. 2006;175(1):63–7; discussion 67–8. 10.1016/S0022-5347(05)00046-7.

    Google Scholar 

  100. Park SY, Jeong W, Ham WS, Kim WT, Rha KH. Initial experience of robotic nephroureterectomy: a hybrid-port technique. BJU Int. 2009;104(11):1718–21. doi:10.1111/j.1464-410X.2009.08671.x.

    Article  PubMed  Google Scholar 

  101. Hu JC, Silletti JP, Williams SB. Initial experience with robot-assisted minimally-invasive nephroureterectomy. J Endourol. 2008;22(4):699–704. doi:10.1089/end.2007.0333.

    Article  PubMed  Google Scholar 

  102. Nanigian DK, Smith W, Ellison LM. Robot-assisted laparoscopic nephroureterectomy. J Endourol. 2006;20(7):463–5; discussion 465–6. 10.1089/end.2006.20.463.

    Google Scholar 

  103. Anderstrom C, Johansson SL, Pettersson S, Wahlqvist L. Carcinoma of the ureter: a clinicopathologic study of 49 cases. J Urol. 1989;142(2 Pt 1):280–3.

    PubMed  CAS  Google Scholar 

  104. Pagano F. Conservative treatment of lower ureteral tumor: modified ureteroneocystostomy for upper urinary tract endoscopic control. J Urol. 1984;132(3):555–7.

    PubMed  CAS  Google Scholar 

  105. Roupret M, Harmon JD, Sanderson KM, et al. Laparoscopic distal ureterectomy and anastomosis for management of low-risk upper urinary tract transitional cell carcinoma: preliminary results. BJU Int. 2007;99(3):623–7. doi:10.1111/j.1464-410X.2006.06688.x.

    Article  PubMed  Google Scholar 

  106. Basiri A, Karami H, Mehrabi S, Javaherforooshzadeh A. Laparoscopic distal ureterectomy and Boari flap ureteroneocystostomy for a low-grade distal ureteral tumor. Urol J. 2008;5(2):120–2.

    PubMed  Google Scholar 

  107. Gerber E, Dinlenc CZ, Wagner JR. Laparoscopic distal ureterectomy for low grade transitional cell carcinoma. J Urol. 2003;169(6):2295. 10.1097/01.ju.0000060883.54360.cd.

    Google Scholar 

  108. Simforoosh N, Mosapour E, Maghsudi R. Laparoscopic ureteral resection and anastomosis for management of low-grade transitional-cell carcinoma. J Endourol. 2005;19(3):287–9. doi:10.1089/end.2005.19.287.

    Article  PubMed  CAS  Google Scholar 

  109. Kundu SD, Eggener SE. Retroperitoneal lymph nodes in transitional cell carcinoma of the kidney and ureter. Adv Urol 2009:181927 Epub. 2009:181927. 10.1155/2009/181927

    Google Scholar 

  110. Hanna MK, Jeffs RD, Sturgess JM, Barkin M. Ureteral structure and ultrastructure. Part I. The normal human ureter. J Urol. 1976;116(6):718–24.

    PubMed  CAS  Google Scholar 

  111. Kondo T, Nakazawa H, Ito F, Hashimoto Y, Toma H, Tanabe K. Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol. 2007;178(4 Pt 1):1212–7; discussion 1217. 10.1016/j.juro.2007.05.158.

    Google Scholar 

  112. Herr HW, Donat SM. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol. 2001;165(1):62–4; discussion 64. 10.1097/00005392-200101000-00015.

    Google Scholar 

  113. Lerner SP, Skinner DG, Lieskovsky G, et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol. 1993;149(4):758–64; discussion 764–5.

    Google Scholar 

  114. Roscigno M, Cozzarini C, Bertini R, et al. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol. 2008;53(4):794–802. doi: 10.1016/j.eururo.2008.01.008.

    Article  PubMed  Google Scholar 

  115. Novara G, De Marco V, Gottardo F, et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer. 2007;110(8):1715–22. doi:10.1002/cncr.22970.

    Article  PubMed  Google Scholar 

  116. Roscigno M, Shariat SF, Margulis V, et al. Impact of lymph node dissection on cancer-specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol. 2009;181(6):2482–9. doi:10.1016/j.juro.2009.02.021.

    Article  PubMed  Google Scholar 

  117. Bolenz C, Shariat SF, Fernandez MI, et al. Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. BJU Int. 2009;103(3):302–6. doi:10.1111/j.1464-410X.2008.07988.x.

    Article  PubMed  Google Scholar 

  118. Zincke H, Neves RJ. Feasibility of conservative surgery for transitional cell cancer of the upper urinary tract. Urol Clin North Am. 1984;11(4):717–24.

    PubMed  CAS  Google Scholar 

  119. Orihuela E, Smith AD. Percutaneous treatment of transitional cell carcinoma of the upper urinary tract. Urol Clin North Am. 1988;15(3):425–31.

    PubMed  CAS  Google Scholar 

  120. Moore K, Khastgir J, Ghei M. Endoscopic management of upper tract urothelial carcinoma. Adv Urol. 2009:620604 Epub. 2009:620604. 10.1155/2009/620604.

    Google Scholar 

  121. Razvi HA, Chun SS, Denstedt JD, Sales JL. Soft-tissue applications of the holmium:YAG laser in urology. J Endourol. 1995;9(5):387–90.

    Article  PubMed  CAS  Google Scholar 

  122. Bagley D, Erhard M. Use of the holmium laser in the upper urinary tract. Tech Urol. 1995;1(1):25–30.

    PubMed  CAS  Google Scholar 

  123. Lam JS, Gupta M. Ureteroscopic management of upper tract transitional cell carcinoma. Urol Clin North Am. 2004;31(1):115–28. doi:10.1016/S0094-0143(03),00099-5.

    Article  PubMed  Google Scholar 

  124. Ziegelbaum M, Novick AC, Streem SB, Montie JE, Pontes JE, Straffon RA. Conservative surgery for transitional cell carcinoma of the renal pelvis. J Urol. 1987;138(5):1146–9.

    PubMed  CAS  Google Scholar 

  125. Martinez-Pineiro JA, Garcia Matres MJ, Martinez-Pineiro L. Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol. 1996;156(2 Pt 1):377–85.

    Google Scholar 

  126. Engelmyer EI, Belis JA. Long-term ureteroscopic management of low-grade transitional cell carcinoma of the upper urinary tract. Tech Urol. 1996;2(2):113–6.

    PubMed  CAS  Google Scholar 

  127. Elliott DS, Blute ML, Patterson DE, Bergstralh EJ, Segura JW. Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma. Urology. 1996;47(6):819–25. doi:10.1016/S0090-4295(96)00043-X.

    Article  PubMed  CAS  Google Scholar 

  128. Sowter SJ, Ilie CP, Efthimiou I, Tolley DA. Endourologic management of patients with upper-tract transitional-cell carcinoma: long-term follow-up in a single center. J Endourol. 2007;21(9):1005–9. doi:10.1089/end.2006.9922.

    Article  PubMed  Google Scholar 

  129. Stewart GD, Tolley DA. What are the oncological risks of minimal access surgery for the treatment of urinary tract cancer? Eur Urol. 2004;46(4):415–20. doi:10.1016/j.eururo.2004.04.030.

    Article  PubMed  Google Scholar 

  130. Roupret M, Traxer O, Tligui M, et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol. 2007;51(3):709–13; discussion 714. 10.1016/j.eururo.2006.07.019.

    Google Scholar 

  131. Jarrett TW, Sweetser PM, Weiss GH, Smith AD. Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience. J Urol. 1995;154(5):1629–35.

    Article  PubMed  CAS  Google Scholar 

  132. Nakada SY, Clayman RV. Percutaneous electrovaporization of upper tract transitional cell carcinoma in patients with functionally solitary kidneys. Urology. 1995;46(5):751–5. doi:10.1016/S0090-4295(99),80318-5.

    Article  PubMed  CAS  Google Scholar 

  133. Huffman JL, Bagley DH, Lyon ES, Morse MJ, Herr HW, Whitmore Jr WF. Endoscopic diagnosis and treatment of upper-tract urothelial tumors. A preliminary report. Cancer. 1985;55(6):1422–8.

    Article  PubMed  CAS  Google Scholar 

  134. Rao PN. Fluid absorption during urological endoscopy. Br J Urol. 1987;60(2):93–9.

    Article  PubMed  CAS  Google Scholar 

  135. Chou CH, Chau T, Yang SS, Lin SH. Acute hyponatremia and renal failure following percutaneous nephrolithotomy. Clin Nephrol. 2003;59(3):237–8.

    PubMed  CAS  Google Scholar 

  136. Storm DW, Fulmer BR. Case report: percutaneous management of transitional-cell carcinoma of the upper urinary tract using the bipolar resectoscope. J Endourol. 2007;21(9):1011–3. doi:10.1089/end.2006.0415.

    Article  PubMed  Google Scholar 

  137. Grasso M. Ureteroscopic management of upper urinary tract urothelial malignancies. Rev Urol. 2000;2(2):116–21.

    PubMed  CAS  Google Scholar 

  138. Schilling A, Bowering R, Keiditsch E. Use of the neodymium-YAG laser in the treatment of ureteral tumors and urethral condylomata acuminata. Clinical experience. Eur Urol. 1986;12 Suppl 1:30–33.

    Google Scholar 

  139. Schmeller NT, Hofstetter AG. Laser treatment of ureteral tumors. J Urol. 1989;141(4):840–3.

    PubMed  CAS  Google Scholar 

  140. Bader MJ, Sroka R, Gratzke C, et al. Laser therapy for upper urinary tract transitional cell carcinoma: indications and management. Eur Urol. 2008. 10.1016/j.eururo.2008.12.012.

    Google Scholar 

  141. Tawfiek ER, Bagley DH. Upper-tract transitional cell carcinoma. Urology. 1997;50(3):321–9. doi:10.1016/S0090-4295(97),00230-6.

    Google Scholar 

  142. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors 1976. J Urol. 2002;167(2 Pt 2):891–3; discussion 893–5.

    Google Scholar 

  143. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–9.

    Article  PubMed  CAS  Google Scholar 

  144. Herr HW. Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin. J Urol. 1985;134(3):531–2.

    PubMed  CAS  Google Scholar 

  145. Bellman GC, Sweetser P, Smith AD. Complications of intracavitary bacillus Calmette-Guerin after ­percutaneous resection of upper tract transitional cell carcinoma. J Urol. 1994;151(1):13–5.

    PubMed  CAS  Google Scholar 

  146. Schnapp DS, Weiss GH, Smith AD. Fever following intracavitary bacillus Calmette-Guerin therapy for upper tract transitional cell carcinoma. J Urol. 1996;156(2 Pt 1):386–8.

    PubMed  CAS  Google Scholar 

  147. Liatsikos EN, Dinlenc CZ, Kapoor R, Smith AD. Transitional-cell carcinoma of the renal pelvis: ureteroscopic and percutaneous approach. J Endourol. 2001;15(4):377–83; discussion 397. 10.1089/089277901300189385.

    Google Scholar 

  148. Chew BH, Pautler SE, Denstedt JD. Percutaneous management of upper-tract transitional cell carcinoma. J Endourol. 2005;19(6):658–63. doi:10.1089/end.2005.19.658.

    Article  PubMed  Google Scholar 

  149. Irie A, Iwamura M, Kadowaki K, Ohkawa A, Uchida T, Baba S. Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology. 2002;59(1):53–7.

    Article  PubMed  Google Scholar 

  150. Yossepowitch O, Lifshitz DA, Dekel Y, et al. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol. 2005;173(3):890–3. doi:10.1097/01.ju.0000147747.89028.64.

    Article  PubMed  Google Scholar 

  151. Rastinehad AR, Smith AD. Bacillus Calmette-Guerin for upper tract urothelial cancer: is there a role? J Endourol. 2009;23(4):563–8. doi:10.1089/end.2008.0164.

    Article  PubMed  Google Scholar 

  152. Clark PE, Streem SB, Geisinger MA. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol. 1999;161(3):772–5; discussion 775–6.

    Google Scholar 

  153. Hayashida Y, Nomata K, Noguchi M, et al. Long-term effects of bacille Calmette-Guerin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract. Urology. 2004;63(6):1084–8. doi:10.1016/j.urology.2004.01.046.

    Article  PubMed  Google Scholar 

  154. Okubo K, Ichioka K, Terada N, Matsuta Y, Yoshimura K, Arai Y. Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure. BJU Int. 2001;88(4):343–7.

    Article  PubMed  CAS  Google Scholar 

  155. Thalmann GN, Markwalder R, Walter B, Studer UE. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol. 2002;168(4 Pt 1):1381–5.

    PubMed  Google Scholar 

  156. Keeley Jr FX, Bagley DH. Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol. 1997;158(6):2074–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, George Washington University, 2150 Pennsylvania Avenue, NW, Washington, DC, 20037, USA

    Jonathan J. Rhee & Thomas W. Jarrett

  2. Department of Pathology and Laboratory Medicine, Princess Margaret Hospital, University Health Network, 200 Elizabeth Street, Toronto, ON, Canada, M5G 2C4

    Theodorus H. van der Kwast

Authors
  1. Jonathan J. Rhee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas W. Jarrett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Theodorus H. van der Kwast
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas W. Jarrett .

Editor information

Editors and Affiliations

  1. Department of Pathology, Cleveland Clinic, Cleveland, 44195, Ohio, USA

    Donna E. Hansel

  2. Department of Pathology, Stanford University Medical Center, Stanford, 94305, California, USA

    Jesse K. McKenney

  3. Glickman Urologic and Kidney Institute, Section of Urologic Oncology, Cleveland Clinic, Cleveland, 44195, Ohio, USA

    Andrew J. Stephenson

  4. Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, 37232-2765, Tennessee, USA

    Sam S. Chang

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rhee, J.J., Jarrett, T.W., van der Kwast, T.H. (2012). Nonneoplastic and Neoplastic Ureteral and Renal Pelvis Disease. In: Hansel, D., McKenney, J., Stephenson, A., Chang, S. (eds) The Urinary Tract. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5320-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5320-8_14

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5319-2

  • Online ISBN: 978-1-4614-5320-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation